Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Häuser W[au]:

EULAR revised recommendations for the management of fibromyalgia. Macfarlane GJ et al. Ann Rheum Dis. (2017)

Cannabinoids in Pain Management and Palliative Medicine. Häuser W et al. Dtsch Arztebl Int. (2017)

Fibromyalgia. Häuser W et al. Nat Rev Dis Primers. (2015)

Search results

Items: 1 to 50 of 766

1.

Fibromyalgia syndrome: under-, over- and misdiagnosis.

Häuser W, Sarzi-Puttini P, Fitzcharles MA.

Clin Exp Rheumatol. 2019 Jan-Feb;37 Suppl 116(1):90-97. Epub 2019 Feb 8. Review.

PMID:
30747096
2.

Diagnosis of Fibromyalgia: Disagreement Between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic.

Wolfe F, Schmukler J, Jamal S, Castrejon I, Gibson KA, Srinivasan S, Häuser W, Pincus T.

Arthritis Care Res (Hoboken). 2019 Feb 6. doi: 10.1002/acr.23731. [Epub ahead of print]

PMID:
30724039
3.

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.

Fitzcharles MA, Zahedi Niaki O, Hauser W, Hazlewood G; the Canadian Rheumatology Association.

J Rheumatol. 2019 Jan 15. pii: jrheum.181120. doi: 10.3899/jrheum.181120. [Epub ahead of print]

PMID:
30647183
4.

Obesity, depression and hip pain.

Schwarze M, Häuser W, Schmutzer G, Brähler E, Beckmann NA, Schiltenwolf M.

Musculoskeletal Care. 2019 Jan 8. doi: 10.1002/msc.1380. [Epub ahead of print]

PMID:
30623588
5.

Medical Cannabis for Older Patients.

Minerbi A, Häuser W, Fitzcharles MA.

Drugs Aging. 2019 Jan;36(1):39-51. doi: 10.1007/s40266-018-0616-5. Review.

PMID:
30488174
6.

Systematic review and meta-analysis on non-opioid analgesics in palliative medicine.

Schüchen RH, Mücke M, Marinova M, Kravchenko D, Häuser W, Radbruch L, Conrad R.

J Cachexia Sarcopenia Muscle. 2018 Dec;9(7):1235-1254. doi: 10.1002/jcsm.12352. Epub 2018 Oct 29. Review.

7.

Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse.

Häuser W, Schubert T, Scherbaum N, Tölle T.

Schmerz. 2018 Oct 16. doi: 10.1007/s00482-018-0331-5. [Epub ahead of print]

PMID:
30327867
8.

The association of adverse childhood experiences and of resilience with chronic noncancer pain in the German adult population - A cross-sectional survey.

Häuser W, Brähler E, Schmutzer G, Glaesmer H.

Eur J Pain. 2019 Mar;23(3):555-564. doi: 10.1002/ejp.1329. Epub 2018 Oct 31.

PMID:
30318676
9.

[A weakly negative recommendation is not an absolute "no" : Comment on AWMF guideline recommendations for cannabis-based medicines in fibromyalgia syndrome].

Häuser W, Petzke F, Nothacker M.

Schmerz. 2018 Oct;32(5):327-329. doi: 10.1007/s00482-018-0328-0. German. No abstract available.

PMID:
30259150
10.

[Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse].

Häuser W, Schubert T, Scherbaum N, Tölle T.

Schmerz. 2018 Dec;32(6):419-426. doi: 10.1007/s00482-018-0324-4. German.

PMID:
30242530
11.

[Errors and Solutions During Medical Therapy for Chronic Pain].

Häuser W, Schuler M.

Dtsch Med Wochenschr. 2018 Sep;143(19):1381-1388. doi: 10.1055/s-0044-102229. Epub 2018 Sep 19. Review. German.

PMID:
30231285
12.

Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias.

Wolfe F, Walitt B, Perrot S, Rasker JJ, Häuser W.

PLoS One. 2018 Sep 13;13(9):e0203755. doi: 10.1371/journal.pone.0203755. eCollection 2018.

13.

Quality of Life of Celiac Patients in Brazil: Questionnaire Translation, Cultural Adaptation and Validation.

Pratesi CP, Häuser W, Uenishi RH, Selleski N, Nakano EY, Gandolfi L, Pratesi R, Zandonadi RP.

Nutrients. 2018 Aug 25;10(9). pii: E1167. doi: 10.3390/nu10091167.

14.

Mirtazapine for fibromyalgia in adults.

Welsch P, Bernardy K, Derry S, Moore RA, Häuser W.

Cochrane Database Syst Rev. 2018 Aug 6;8:CD012708. doi: 10.1002/14651858.CD012708.pub2. Review.

PMID:
30080242
15.

European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management.

Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, Perrot S, Schäfer M, Wells C, Brill S.

Eur J Pain. 2018 Oct;22(9):1547-1564. doi: 10.1002/ejp.1297. Epub 2018 Sep 4.

PMID:
30074291
16.

Primary and Secondary Fibromyalgia Are The Same: The Universality of Polysymptomatic Distress.

Wolfe F, Walitt B, Rasker JJ, Häuser W.

J Rheumatol. 2019 Feb;46(2):204-212. doi: 10.3899/jrheum.180083. Epub 2018 Jul 15.

PMID:
30008459
17.

Efficacy, acceptability and safety of Internet-delivered psychological therapies for fibromyalgia syndrome: A systematic review and meta-analysis of randomized controlled trials.

Bernardy K, Klose P, Welsch P, Häuser W.

Eur J Pain. 2019 Jan;23(1):3-14. doi: 10.1002/ejp.1284. Epub 2018 Aug 6. Review.

PMID:
29984490
18.

Facts and myths pertaining to fibromyalgia.

Häuser W, Fitzcharles MA.

Dialogues Clin Neurosci. 2018 Mar;20(1):53-62. Review.

19.

[Psychosomatics in gastroenterology - statement of the Work Group for Psychosomatics in Gastroenterology of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)].

Auer PG, Enck P, Häuser W, Stengel A, Storr M, Langhorst J; AG Psychosomatik in der Gastroenterologie der DGVS.

Z Gastroenterol. 2018 Jun;56(6):684-689. doi: 10.1055/a-0599-1248. Epub 2018 Jun 11. German.

PMID:
29890563
20.

Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: a methodological and political minefield.

Häuser W, Finnerup NB, Moore RA.

Pain. 2018 Oct;159(10):1906-1907. doi: 10.1097/j.pain.0000000000001295. No abstract available.

PMID:
29847473
21.

Comorbid fibromyalgia: A qualitative review of prevalence and importance.

Fitzcharles MA, Perrot S, Häuser W.

Eur J Pain. 2018 Oct;22(9):1565-1576. doi: 10.1002/ejp.1252. Epub 2018 Jun 22. Review.

PMID:
29802812
22.

Reply to Garg et al, Smith et al, and Persichino and Miller.

White AC Jr, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE.

Clin Infect Dis. 2018 Nov 13;67(11):1798. doi: 10.1093/cid/ciy437. No abstract available.

PMID:
29790917
23.

Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis.

Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B.

Z Gastroenterol. 2018 Oct;56(10):1267-1275. doi: 10.1055/a-0605-4080. Epub 2018 May 9.

PMID:
29742780
24.

[Chronic pain disorder with somatic and psychological factors : A diagnosis initiated by professional politics awaits its scientific validation].

Häuser W.

Schmerz. 2018 Jun;32(3):211-212. doi: 10.1007/s00482-018-0296-4. German. No abstract available.

PMID:
29693199
25.

Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE.

Am J Trop Med Hyg. 2018 Apr;98(4):945-966. doi: 10.4269/ajtmh.18-88751. No abstract available.

26.

Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

White AC Jr, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE.

Clin Infect Dis. 2018 Apr 3;66(8):1159-1163. doi: 10.1093/cid/ciy157. No abstract available.

PMID:
29617787
27.

The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.

Thapa K, Romo ML, Carpio A, Leslie D, Andrews H, Hauser WA, Kelvin EA.

Trans R Soc Trop Med Hyg. 2018 Feb 1;112(2):73-80. doi: 10.1093/trstmh/try023.

28.

In Reply.

Häuser W.

Dtsch Arztebl Int. 2018 Mar 2;115(9):143-144. doi: 10.3238/arztebl.2018.0143b. No abstract available.

29.

Cannabis-based medicines for chronic neuropathic pain in adults.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W.

Cochrane Database Syst Rev. 2018 Mar 7;3:CD012182. doi: 10.1002/14651858.CD012182.pub2. Review.

PMID:
29513392
30.

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.

Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W.

Cochrane Database Syst Rev. 2018 Feb 28;2:CD010292. doi: 10.1002/14651858.CD010292.pub2. Review.

31.

Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

White AC Jr, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE.

Clin Infect Dis. 2018 Apr 3;66(8):e49-e75. doi: 10.1093/cid/cix1084. No abstract available.

PMID:
29481580
32.

Self-reported childhood maltreatment, lifelong traumatic events and mental disorders in American and Israeli rheumatoid arthritis patients.

Merdler-Rabinowicz R, Hassidim A, Hellou R, Merdler I, Hauser W, Ablin JN.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):575-580. Epub 2018 Feb 15.

33.

Systematic review and meta-analysis of cannabinoids in palliative medicine.

Mücke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H, Radbruch L, Häuser W, Conrad R.

J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):220-234. doi: 10.1002/jcsm.12273. Epub 2018 Feb 5. Review.

34.

The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents.

Häuser W, Schug S, Furlan AD.

Pain Rep. 2017 May 12;2(3):e599. doi: 10.1097/PR9.0000000000000599. eCollection 2017 May.

35.

Diagnostic confounders of chronic widespread pain: not always fibromyalgia.

Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA.

Pain Rep. 2017 Apr 30;2(3):e598. doi: 10.1097/PR9.0000000000000598. eCollection 2017 May. Review.

36.

The Perils of Overestimating the Efficacy of Cannabis-Based Medicines for Chronic Pain Management.

Hauser W, Fitzcharles MA.

Pain Physician. 2018 Jan;21(1):E79-E80. No abstract available.

37.

Questioning the Effectiveness of Newer Antiseizure Medications.

Hauser WA.

JAMA Neurol. 2018 Mar 1;75(3):273-274. doi: 10.1001/jamaneurol.2017.3069. No abstract available.

PMID:
29279885
38.
39.

Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews.

Häuser W, Petzke F, Fitzcharles MA.

Eur J Pain. 2018 Mar;22(3):455-470. doi: 10.1002/ejp.1118. Epub 2017 Oct 15.

PMID:
29034533
40.

Problematic use of prescribed opioids for chronic noncancer pain-no scarcity of data outside the United States.

Häuser W, Tölle T.

Pain. 2017 Nov;158(11):2277. doi: 10.1097/j.pain.0000000000001048. No abstract available.

PMID:
29028748
41.

Cannabinoids in Pain Management and Palliative Medicine.

Häuser W, Fitzcharles MA, Radbruch L, Petzke F.

Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634. doi: 10.3238/arztebl.2017.0627. Review.

42.

WITHDRAWN: Anticonvulsants for fibromyalgia.

Üçeyler N, Sommer C, Walitt B, Häuser W.

Cochrane Database Syst Rev. 2017 Oct 9;10:CD010782. doi: 10.1002/14651858.CD010782.pub2. Review.

PMID:
28991361
43.

Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome - A systematic review and meta-analysis of randomized controlled trials.

Bernardy K, Klose P, Welsch P, Häuser W.

Eur J Pain. 2018 Feb;22(2):242-260. doi: 10.1002/ejp.1121. Epub 2017 Oct 6. Review.

PMID:
28984402
44.
45.

Unravelling Fibromyalgia-Steps Toward Individualized Management.

Häuser W, Perrot S, Clauw DJ, Fitzcharles MA.

J Pain. 2018 Feb;19(2):125-134. doi: 10.1016/j.jpain.2017.08.009. Epub 2017 Sep 21.

PMID:
28943233
46.

[Erratum to: Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Eich W, Bär KJ, Bernateck M, Burgmer M, Dexl C, Petzke F, Sommer C, Winkelmann A, Häuser W.

Schmerz. 2017 Dec;31(6):620. doi: 10.1007/s00482-017-0244-8. German. No abstract available.

PMID:
28884194
47.

Erratum zu: Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen. Eine systematische Übersichtsarbeit von randomisierten, kontrollierten Studien.

Petzke F, Enax-Krumova EK, Häuser W.

Schmerz. 2017 Dec;31(6):619. doi: 10.1007/s00482-017-0242-x. German. No abstract available.

PMID:
28879387
48.

Fetal growth and premature delivery in pregnant women on antiepileptic drugs.

Hernández-Díaz S, McElrath TF, Pennell PB, Hauser WA, Yerby M, Holmes LB; North American Antiepileptic Drug Pregnancy Registry.

Ann Neurol. 2017 Sep;82(3):457-465. doi: 10.1002/ana.25031. Erratum in: Ann Neurol. 2018 Apr;83(4):872.

PMID:
28856694
49.

[Choosing wisely together in pain medicine].

Häuser W, Keidel M.

Schmerz. 2017 Oct;31(5):431-432. doi: 10.1007/s00482-017-0243-9. German. No abstract available.

PMID:
28840374
50.

Utility of EEG Activation Procedures in Epilepsy: A Population-Based Study.

Baldin E, Hauser WA, Buchhalter JR, Hesdorffer DC, Ottman R.

J Clin Neurophysiol. 2017 Nov;34(6):512-519. doi: 10.1097/WNP.0000000000000371.

Supplemental Content

Loading ...
Support Center